ReviewEndocrine reviews2021
Hormonal Therapy for Prostate Cancer.
Review in Endocrine reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 262 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
262 citing papers in PubMed, 7 syntheses or guidelines pooled it, 406 citations in OpenAlex.
- Impact of PSMA PET on the management and clinical outcomes of patients with biochemical failure of prostate cancer after definitive treatment: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Comparative fall risk of patients treated with novel androgen receptor antagonists in prostate cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- A meta-analysis of dizziness as an adverse reaction in novel endocrine therapy for advanced prostate cancer.BMC cancer · 2026Pooled it
- Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis.Future oncology (London, England) · 2026Pooled it
- The efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer: a meta-analysis based on subgroups and reconstructed individual patient data.International urology and nephrology · 2026Pooled it
- Psychosocial experiences of prostate cancer survivors after treatment: a systematic review of qualitative studies.Frontiers in public health · 2025Pooled it
- Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review.Frontiers in oncology · 2024Pooled it
- Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis.Age and ageing · 2026Trial
- HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.Cell reports. Medicine · 2024Trial
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Article
- Survival and Mortality Predictors in Prostate Cancer: A Retrospective Cohort of 10 556 Brazilian Patients.Cancer reports (Hoboken, N.J.) · 2026Article
- Dyadic Coping and Its Influencing Factors in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy and Their Spouses: A Latent Class Analysis.Journal of clinical nursing · 2026Observational
- SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer.Journal of biochemical and molecular toxicology · 2026Article
- Unlocking the Anticancer Potential of Patchouli Leaves: Molecular Mechanisms and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction.JAMA network open · 2026Article
- Article
- Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026Review
- DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer.Redox biology · 2026Article
- TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways.Cell death and differentiation · 2026Article
202 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Huggins and Hodges demonstrated the therapeutic effect of gonadal testosterone deprivation in the 1940s and therefore firmly established the concept that prostate cancer is a highly androgen-dependent disease. Since that time, hormonal therapy has undergone iterative advancement, from the types of gonadal testosterone deprivation to modalities that block the generation of adrenal and other extragonadal androgens, to those that directly bind and inhibit the androgen receptor (AR). The clinical states of prostate cancer are the product of a superimposition of these therapies with nonmetastatic advanced prostate cancer, as well as frankly metastatic disease. Today's standard of care for advanced prostate cancer includes gonadotropin-releasing hormone agonists (e.g., leuprolide), second-generation nonsteroidal AR antagonists (enzalutamide, apalutamide, and darolutamide) and the androgen biosynthesis inhibitor abiraterone. The purpose of this review is to provide an assessment of hormonal therapies for the various clinical states of prostate cancer. The advancement of today's standard of care will require an accounting of an individual's androgen physiology that also has recently recognized germline determinants of peripheral androgen metabolism, which include HSD3B1 inheritance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.